Last reviewed · How we verify

Fotemustine and Ipilimumab — Competitive Intelligence Brief

Fotemustine and Ipilimumab (Fotemustine and Ipilimumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy + immune checkpoint inhibitor combination. Area: Oncology.

phase 3 Chemotherapy + immune checkpoint inhibitor combination DNA alkylation (fotemustine); CTLA-4 (ipilimumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fotemustine and Ipilimumab (Fotemustine and Ipilimumab) — Italian Network for Tumor Biotherapy Foundation. Fotemustine is a nitrosourea chemotherapy agent combined with ipilimumab, a CTLA-4 inhibitor that enhances anti-tumor immunity by blocking immune checkpoint inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fotemustine and Ipilimumab TARGET Fotemustine and Ipilimumab Italian Network for Tumor Biotherapy Foundation phase 3 Chemotherapy + immune checkpoint inhibitor combination DNA alkylation (fotemustine); CTLA-4 (ipilimumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy + immune checkpoint inhibitor combination class)

  1. Italian Network for Tumor Biotherapy Foundation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fotemustine and Ipilimumab — Competitive Intelligence Brief. https://druglandscape.com/ci/fotemustine-and-ipilimumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: